Vaginal ring delivery of selective progesterone receptor modulators for contraception

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Vaginal ring delivery of selective progesterone receptor modulators (SPRMs) is under development to address the limitations of current hormonal methods that affect use and effectiveness. This method would be appropriate for use in women with contraindications to, or preferences to avoid, estrogens. A contraceptive vaginal ring (CVR) also eliminates the need for daily dosing and therefore might improve the effectiveness of contraception. The principal contraceptive effect of SPRMs is the suppression of ovulation. One limiting factor of chronic SPRM administration is the development of benign endometrial thickening characterized as PRM-associated endometrial changes. Ulipristal acetate (UPA) is approved for use as an emergency contraceptive pill, but no SPRM is approved for regular contraception. The Population Council is developing an ulipristal acetate CVR for regular contraception. The CVR studied is of a matrix design composed of micronized UPA mixed in a silicone rubber matrix The target product is a ring designed for continuous use over 3 months delivering near steady-state drug levels that will suppress ovulation. Results from Phase 1 and 2 studies demonstrate that suppression of ovulation occurs with UPA levels above 6-7 ng/mL.

Original languageEnglish (US)
Pages (from-to)314-318
Number of pages5
JournalContraception
Volume87
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Female Contraceptive Devices
Progesterone Receptors
Contraceptive Agents
Contraception
Ovulation Inhibition
Postcoital Contraceptives
Silicone Elastomers
Ovulation
Estrogens
ulipristal acetate
Pharmaceutical Preparations
Population

Keywords

  • Contraceptive
  • Ovulation
  • Progesterone-receptor modulator
  • Suppression
  • Ulipristal
  • Vaginal ring

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Vaginal ring delivery of selective progesterone receptor modulators for contraception. / Jensen, Jeffrey.

In: Contraception, Vol. 87, No. 3, 03.2013, p. 314-318.

Research output: Contribution to journalArticle

@article{e5dba320db1e4320ae4c1445d1456aaf,
title = "Vaginal ring delivery of selective progesterone receptor modulators for contraception",
abstract = "Vaginal ring delivery of selective progesterone receptor modulators (SPRMs) is under development to address the limitations of current hormonal methods that affect use and effectiveness. This method would be appropriate for use in women with contraindications to, or preferences to avoid, estrogens. A contraceptive vaginal ring (CVR) also eliminates the need for daily dosing and therefore might improve the effectiveness of contraception. The principal contraceptive effect of SPRMs is the suppression of ovulation. One limiting factor of chronic SPRM administration is the development of benign endometrial thickening characterized as PRM-associated endometrial changes. Ulipristal acetate (UPA) is approved for use as an emergency contraceptive pill, but no SPRM is approved for regular contraception. The Population Council is developing an ulipristal acetate CVR for regular contraception. The CVR studied is of a matrix design composed of micronized UPA mixed in a silicone rubber matrix The target product is a ring designed for continuous use over 3 months delivering near steady-state drug levels that will suppress ovulation. Results from Phase 1 and 2 studies demonstrate that suppression of ovulation occurs with UPA levels above 6-7 ng/mL.",
keywords = "Contraceptive, Ovulation, Progesterone-receptor modulator, Suppression, Ulipristal, Vaginal ring",
author = "Jeffrey Jensen",
year = "2013",
month = "3",
doi = "10.1016/j.contraception.2012.08.038",
language = "English (US)",
volume = "87",
pages = "314--318",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Vaginal ring delivery of selective progesterone receptor modulators for contraception

AU - Jensen, Jeffrey

PY - 2013/3

Y1 - 2013/3

N2 - Vaginal ring delivery of selective progesterone receptor modulators (SPRMs) is under development to address the limitations of current hormonal methods that affect use and effectiveness. This method would be appropriate for use in women with contraindications to, or preferences to avoid, estrogens. A contraceptive vaginal ring (CVR) also eliminates the need for daily dosing and therefore might improve the effectiveness of contraception. The principal contraceptive effect of SPRMs is the suppression of ovulation. One limiting factor of chronic SPRM administration is the development of benign endometrial thickening characterized as PRM-associated endometrial changes. Ulipristal acetate (UPA) is approved for use as an emergency contraceptive pill, but no SPRM is approved for regular contraception. The Population Council is developing an ulipristal acetate CVR for regular contraception. The CVR studied is of a matrix design composed of micronized UPA mixed in a silicone rubber matrix The target product is a ring designed for continuous use over 3 months delivering near steady-state drug levels that will suppress ovulation. Results from Phase 1 and 2 studies demonstrate that suppression of ovulation occurs with UPA levels above 6-7 ng/mL.

AB - Vaginal ring delivery of selective progesterone receptor modulators (SPRMs) is under development to address the limitations of current hormonal methods that affect use and effectiveness. This method would be appropriate for use in women with contraindications to, or preferences to avoid, estrogens. A contraceptive vaginal ring (CVR) also eliminates the need for daily dosing and therefore might improve the effectiveness of contraception. The principal contraceptive effect of SPRMs is the suppression of ovulation. One limiting factor of chronic SPRM administration is the development of benign endometrial thickening characterized as PRM-associated endometrial changes. Ulipristal acetate (UPA) is approved for use as an emergency contraceptive pill, but no SPRM is approved for regular contraception. The Population Council is developing an ulipristal acetate CVR for regular contraception. The CVR studied is of a matrix design composed of micronized UPA mixed in a silicone rubber matrix The target product is a ring designed for continuous use over 3 months delivering near steady-state drug levels that will suppress ovulation. Results from Phase 1 and 2 studies demonstrate that suppression of ovulation occurs with UPA levels above 6-7 ng/mL.

KW - Contraceptive

KW - Ovulation

KW - Progesterone-receptor modulator

KW - Suppression

KW - Ulipristal

KW - Vaginal ring

UR - http://www.scopus.com/inward/record.url?scp=84873409607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873409607&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2012.08.038

DO - 10.1016/j.contraception.2012.08.038

M3 - Article

C2 - 23040126

AN - SCOPUS:84873409607

VL - 87

SP - 314

EP - 318

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 3

ER -